Peptides for muscle growth: human evidence

What human studies show.

None of the substances reviewed here has strong human evidence for more muscle or better strength in healthy adults. Some change growth hormone or IGF-1, a growth-related body signal. Some studies in people with specific health conditions found changes in lean mass or body scans. Those results do not prove that a retail vial builds useful muscle, strength, or physical function.

“Peptides for muscle growth” can refer to very different products. It can mean an FDA-approved medicine for one disease. It can also mean a drug in a formal study, an unapproved clinic injection, a research chemical, or a collagen supplement. Evidence for one product does not automatically apply to another.

For each substance, the sections below record what a study measured, who took part, and which exact product was used. No dose, treatment plan, eligibility decision, or treatment recommendation is given here.

Start with the result a study measured.

Muscle marketing often turns one body measurement into a larger promise. A higher hormone level does not show that new muscle formed. Lean mass counts muscle, water, and other non-fat tissue. A scan showing more muscle area does not prove greater strength, endurance, mobility, or sports performance.

The strongest evidence would come from more than one controlled study in the intended group of people. Those studies would measure muscle size, strength, or daily function. They would also report enough follow-up and safety information. Most promoted injectable peptides lack that record.

• How it might work: an effect in a cell, at a receptor, or in an animal, which does not measure muscle in people
• Body response: a change in growth hormone (GH), IGF-1, or another body marker, which alone does not show a health benefit
• Body makeup: lean mass or fat-free mass, which includes water as well as muscle
• Muscle structure: a scan or tissue sample that measures muscle area, volume, or fiber size
• Performance: a measure of strength, power, exercise ability, or recovery time
• Daily function: a measure of mobility, independence, symptoms, or return to usual activity

CJC-1295 and ipamorelin: hormone changes and muscle results.

CJC-1295 is a changed, longer-acting version of growth hormone-releasing hormone, a body signal. Two small studies assigned healthy adults to groups by chance. They compared several study doses with an inactive comparison (placebo). The studies measured how the substance moved through the body, hormone levels, and short-term side effects.

The CJC-1295 studies found lasting increases in growth hormone (GH) and insulin-like growth factor 1 (IGF-1). They did not measure muscle size, strength, response to training, or physical function.

A larger hormone signal does not prove a health benefit. Studies of growth hormone itself show why lean-mass claims need care.

A review combined controlled studies of growth hormone in healthy, physically fit young people. It found more lean body mass and no clear improvement in strength or exercise ability. It also found more fluid swelling and fatigue.

A later controlled study found that some of the extra lean mass was water outside the cells. Most performance measures did not improve, and one sprint result improved for a short time.

Those growth-hormone studies did not test CJC-1295, so they cannot show whether CJC-1295 has the same effects. They do show why “raises GH” does not mean “builds useful muscle.” The controlled CJC-1295 studies in people reviewed here have not shown better muscle growth, strength, or function.

Marketing pages often group ipamorelin, GHRP-2, GHRP-6, and similar substances with CJC-1295. A registered ipamorelin study in people addressed recovery of gut function after bowel surgery. It did not show muscle growth or strength in healthy adults.

Neither CJC-1295 nor ipamorelin has an FDA-approved drug product or an approved use for muscle growth. A listing on a clinic menu does not change that status or supply the missing evidence.

A study of one ingredient does not prove that a two-ingredient product works. Two ideas about how substances might act also do not add up to a measured health result. This review found no completed controlled human study of the CJC-1295 and ipamorelin combination for body-building claims. No such study showed more muscle, strength, or function.

FDA's current compounding-risk page says human data for CJC-1295 are limited. The page reports serious events linked with CJC-1295, including increased heart rate and a systemic vasodilatory reaction. That term means blood vessels widen across the body.

For some injected forms of ipamorelin acetate, FDA says it lacks enough information to know whether the drug would cause harm. These statements do not rank one product as safer than another.

Tesamorelin is approved for a narrow use.

Tesamorelin's current FDA label covers reducing excess abdominal fat in adults with HIV and lipodystrophy. Lipodystrophy causes unusual changes in body fat. The label says the product is not for weight-loss management and is weight neutral.

Tesamorelin is not approved for body building, sports performance, or general age-related muscle loss. That approval stays tied to one product and use.

A later analysis of earlier studies reported changes in trunk-muscle area and density in people with HIV and abdominal obesity. The analysis included only tesamorelin participants who had already reached a set reduction in deep abdominal fat. The comparison group was not selected by the same rule after treatment started.

This comparison no longer kept the original groups that were assigned by chance. The analysis also did not show better strength, performance, or daily function. The authors said more research was needed on long-term results, daily life, and people without HIV.

That result applies to people with HIV and abdominal obesity. It does not show a general muscle-growth benefit for healthy adults.

The label also lists reasons not to use the product and serious warnings. These cover active cancer, damage to the brain system that controls growth hormone, high IGF-1, fluid buildup, blood-sugar problems, and serious allergic reactions. FDA's approval of one product for a narrow use does not support an unapproved use or a different compounded product.

BPC-157 and TB-500: recovery claims and the human record.

BPC-157 and TB-500 are often promoted with injury-healing or “recovery” stories. Less pain, tendon repair, wound healing, return to training, muscle growth, and strength are separate results. Evidence for one of these results does not prove another.

A small Phase 1 study of BPC-157 was registered years ago on ClinicalTrials.gov. Phase 1 is an early safety stage. The study covered BPC-157 safety and how it moved through the body.

Its status is unknown, and the record has no posted results. The record does not show muscle repair or growth.

FDA found no or only limited safety information for the proposed routes. FDA also lacks enough information to know whether compounded BPC-157 would cause harm.

For the TB-500 fragment, FDA found no data from people who received it in drug products. FDA also lacks important safety information. Research on full-length thymosin beta-4, animal tissue repair, or lab actions does not automatically apply to the short fragment sold as TB-500. The sources reviewed here include no controlled human study showing better muscle growth or strength from BPC-157 or TB-500.

PEG-MGF, IGF-1 analogues, and follistatin: early-stage claims.

Names such as PEG-MGF, IGF-1 LR3, and follistatin come from real body pathways involved in growth and muscle control. A pathway name alone does not show a health result. A chemical change can affect how a substance moves through the body and how it acts.

It can also affect impurities and risks. Evidence about natural IGF-1, mechano growth factor, or full proteins does not automatically apply to a changed product with a related name.

FDA says it has not found data from people who received drug products containing PEG-MGF. FDA also lacks enough information to know whether PEG-MGF would cause harm. In one warning letter, FDA listed products made with follistatin and IGF1-LR3 as unapproved drugs. The products did not meet the compounding exceptions cited in that letter.

This review found no controlled human studies showing that retail versions of these products improve muscle size, strength, or function.

“No adequate controlled human evidence found” means good human studies have not shown enough to estimate a benefit or compare it with possible harm. That finding does not establish that a product is “proven ineffective.”

Collagen peptides are a separate supplement question.

Hydrolyzed collagen peptides are food-based protein ingredients taken by mouth. Injected hormone-like drugs and research chemicals are a separate product category.

One small study assigned older men with age-related muscle loss to groups by chance. It found differences in fat-free mass and strength when collagen was added to supervised strength training. Both groups did the training.

The result applies to one supplement, one group, and one training program. It does not show that a drug-like peptide builds muscle without training.

How far the result reaches depends on who was studied and what the other group received. Usual protein intake, study methods, study size, funding, and repeat studies also matter. One study does not prove that all collagen products work. A result for dietary collagen also does not prove that CJC-1295, BPC-157, TB-500, or another injection works.

Safety concerns about an unapproved injection also do not automatically apply to a common food-based supplement. The broad word “peptide” tells a reader little until the product category is clear.

Product identity and safety are part of the evidence.

Known: a published study supports only the product and study plan that researchers used. A vial with the same ingredient name can differ in sequence, chemical form, amount, inactive ingredients, impurities, storage, or route. A route is how a product enters the body.

Sterility and stability controls can also differ. A “research use only” lab report does not show FDA approval. It also does not prove a health benefit, sterility, or that a product is suitable for injection.

Known: compounded drugs can meet a real patient need when an approved product is not medically suitable. Compounded drugs are not FDA-approved. FDA does not review each one for safety, effectiveness, or quality before marketing.

That missing review does not show that a given compounded preparation is defective. Evidence for an approved product also does not automatically apply to it.

Unknown: short studies of hormone levels cannot rule out uncommon harms or show long-term tradeoffs. For unapproved peptides with little or no human exposure information, both benefit and harm remain uncertain. Do not apply an approved-product study, or a lack of reported problems, to a different vial.

Tested athletes have separate, current anti-doping rules.

The World Anti-Doping Agency (WADA) sets rules for athletes covered by its code. Its 2026 Prohibited List took effect on January 1, 2026. Section S0 prohibits non-approved drugs such as BPC-157.

Section S2 names several groups. These include drugs made to act like growth hormone-releasing hormone, such as CJC-1295, sermorelin, and tesamorelin. It also names substances that signal the body to release growth hormone, such as ipamorelin.

It covers growth factors and related substances. Examples include mechano growth factors, follistatin, and thymosin-beta-4 derivatives such as TB-500. These groups are prohibited at all times, in and out of competition.

The information here cannot clear a substance or product for tested sport. A prescription, clinic statement, or ingredient label does not prove that WADA permits it. A broad group can prohibit a substance that the list does not name as an example. A prescription alone does not grant a therapeutic use exemption, which is formal permission for a necessary medical use.

A product label also does not prove that the contents match the label. Rules can change, and a sport can add requirements. Athletes and support staff should check the current WADA list and their anti-doping organization's rules. This article was checked against the 2026 list on August 2, 2026.

Check a muscle claim against the cited study.

Start by writing the sales claim in words that can be measured. A phrase such as “Supports muscle” is too vague. A measurable claim names the exact product and people.

It also names the study length, comparison group, measured result, and size of the change. Then check whether the cited human study matches each part.

• Exact molecule, chemical form, finished product, and how it enters the body
• Approved product, lawful compounded preparation, study drug, research chemical, or food supplement
• People in the study compared with people targeted by the sales claim
• Direct muscle-size, strength, or function result, in addition to any body marker
• Controlled human results, study length, size of the change, uncertainty, and unwanted events
• Current FDA status and, for tested sport, the current prohibited list